HMGA1在结直肠癌中的表达及斑螯干预后的作用研究
摘要
结直肠癌（colorectal cancer, CRC）是比较常见的消化道恶性肿瘤，它的发病率仅次于胃癌和食道癌，高居全球恶性肿瘤的第四位，每年新增患者约100万人，每年因CRC死亡的人数约50万人。近年来，CRC的发病率正在逐渐增加。同时患者的发病年龄也趋于年轻化。研究显示，结直肠癌的好发部位多为直肠和直肠、乙状结直肠的交界处，占60%左右，发病年龄多在60~70岁之间，50岁以下者还不到20%。CRC前期治疗主要是以手术治疗为主，晚期则是以放化疗为主。据报道，CRC的死亡原因主要由于肿瘤的复发和转移。已有研究表明，HMGA1参与了许多和肿瘤相关基因的转录和调控的过程。另有研究发现，HMGA1在癌细胞中的含量极其丰富，说明HMGA1可能改变染色质的结构。目前，HMGA1在CRC中的高表达具体机制尚未明确。因此，探讨HMGA1在CRC中发病机制中的作用对于临床研究具有重要的现实意义。近年研究表明，S100A3作为S100蛋白家族中重要的癌症因子，已被众多学者公认和广泛的研究。然而，是否S100A3在结直肠癌中发挥着同样重要的作用呢？如果S100A3在结直肠癌中发挥作用，那么与HMGA1蛋白的关系如何呢?
据国内文献报道称，斑蝥是昆虫大斑蝥或者小斑蝥的黄黑色干燥体,拥有攻毒蚀疮、具有逐痪散结的独特功效,人类应用斑蝥治疗癌症疾病已有200多年的发展历史。斑蝥可通过抑制癌细胞对氨基酸的摄取，从而抑制蛋白质的合成，同时刺激淋巴细胞、巨噬细胞及多形核细胞产生白介素，从而提高机体免疫力，增加机体抵抗力，加大对肿瘤细胞的杀伤力而达到治疗的目的；斑蝥抗癌机理则是抑制癌细胞DNA以及蛋白质合成，控制癌细胞线粒体的呼吸和酶的活性。斑蝥素在抑制肿瘤的同时，不降低外周血中的白细胞数量，对机体没有显著的免疫抑制作用，这在抗肿瘤药物中是很少见的，因此备受人们关注。近年来，随着抗肿瘤中药优势的凸显，人们对斑蝥素及它的衍生物的研究越来越多，其中对斑蝥素，斑蝥素酸钠及去甲斑蝥素的研究最多，迄今为止，国内外对于结直肠癌的抑制作用尚未明确。那么，斑蝥是否可以降低结直肠癌中S100A3和HMGA1的表达，进而起到与化疗药相似的治疗效果呢？本实验将对S100A3蛋白和HMGA1蛋白可能的相互关系进行研究；另外，探讨S100A3和HMGA1蛋白在结直肠癌组织发病机制中的作用以及斑蝥干预后对S100A3蛋白和HMGA1蛋白表达的影响，从而揭示S100A3蛋白和HMGA1蛋白在结直肠癌中的中作用以及斑蝥对结直肠癌干预后的影响，为今后防治结直肠癌提供新的依据。
CRC is a kind of malignant lesions of colorectal epithelium in a variety ofenvironmental or genetic factors. It is one of the common malignant lesions. Globalannual new cases of CRC are about100million people, accounting for10%of allmalignant tumors to15%.
High expression of HMGA1can be induced malignant transformation of normalcells. The amount of HMGA1expression is biggest in embryonic development. Itsexpression reduced in fully differentiated mature cells or was not expressed. Thereaseach between S100A3and tumor was few compared to other members of thefamily of calcium-binding S100A.The affinity of S100A3can be considered as azinc ion signaling proteins. S100A3expression may be involved in malignanttransformation in the absence of early breast cells. Whether S100A3and HMGA1play an important role in CRC?
Cantharides are commonly known as Meloidae spot lytta insects. Cantharidinatewas a special effect for primary liver cancer. Cantharidinate was used more and morewidely. It was also gradually in-depth study. In recent years, study of cantharidinatemainly focused on the synthesis, biological functions, toxicity and physiologicalaspects in the United States and European countries. Anticancer mechanisms,pharmacology and applied research of cantharidinate were more in our country. Butthe cantharidinate for prevention and treatment of CRC had not been reported.
This study investigated the preventive and therapeutic effects of cantharidinate onhuman colorectal cancer both in vivo and in vitro. In addition, the mechanismsinvolved in origination and development of renal interstitial fibrosis also beenapproached. The main research contents is composed of①the relationship ofHMGA1and S100A3may be linked and investigated the role of HMGA1and S100A3in human CRC②the role of cantharidinate are observed for CRC③Theinhibition role and effect of cantharidinate are investigated for HMGA1and S100A3gene in human colorectal cancer.④The effect of cantharidinate is analyzed byRaman spectra.
Main results were as follows:
1. The protein expression of HMGA1and S100A3was significantly increasedin cancer tissues compared with the adjacent tissues.
2. The expression of S100A3and HMGA1may be correlated in CRC.
3. Immunohistochemistry and Western blot results confirmed that theexpression of HMGA1and S100A3was significantly increased in cancer tissuecompared with adjacent tissues (P <0.05and P <0.01).
4. After intervention of cantharidinate, Cell cycle occurs more obvious changesin colorectal cancer.The expression of HMGA1and S100A3decreased gradually(P<0.05). Its protein structure also improved after intervention of cantharidinatethrough Raman spectra.Conclusions were as follows:
1. S100A3and HMGA1play an important role in colorectal cancer.
2. Cantharidinate is similar with chemotherapy, it can reduce the gene andprotein expression of S100A3and HMGA1in tumor cells and improve cycle.
据国内文献报道称，斑蝥是昆虫大斑蝥或者小斑蝥的黄黑色干燥体,拥有攻毒蚀疮、具有逐痪散结的独特功效,人类应用斑蝥治疗癌症疾病已有200多年的发展历史。斑蝥可通过抑制癌细胞对氨基酸的摄取，从而抑制蛋白质的合成，同时刺激淋巴细胞、巨噬细胞及多形核细胞产生白介素，从而提高机体免疫力，增加机体抵抗力，加大对肿瘤细胞的杀伤力而达到治疗的目的；斑蝥抗癌机理则是抑制癌细胞DNA以及蛋白质合成，控制癌细胞线粒体的呼吸和酶的活性。斑蝥素在抑制肿瘤的同时，不降低外周血中的白细胞数量，对机体没有显著的免疫抑制作用，这在抗肿瘤药物中是很少见的，因此备受人们关注。近年来，随着抗肿瘤中药优势的凸显，人们对斑蝥素及它的衍生物的研究越来越多，其中对斑蝥素，斑蝥素酸钠及去甲斑蝥素的研究最多，迄今为止，国内外对于结直肠癌的抑制作用尚未明确。那么，斑蝥是否可以降低结直肠癌中S100A3和HMGA1的表达，进而起到与化疗药相似的治疗效果呢？本实验将对S100A3蛋白和HMGA1蛋白可能的相互关系进行研究；另外，探讨S100A3和HMGA1蛋白在结直肠癌组织发病机制中的作用以及斑蝥干预后对S100A3蛋白和HMGA1蛋白表达的影响，从而揭示S100A3蛋白和HMGA1蛋白在结直肠癌中的中作用以及斑蝥对结直肠癌干预后的影响，为今后防治结直肠癌提供新的依据。
CRC is a kind of malignant lesions of colorectal epithelium in a variety ofenvironmental or genetic factors. It is one of the common malignant lesions. Globalannual new cases of CRC are about100million people, accounting for10%of allmalignant tumors to15%.
High expression of HMGA1can be induced malignant transformation of normalcells. The amount of HMGA1expression is biggest in embryonic development. Itsexpression reduced in fully differentiated mature cells or was not expressed. Thereaseach between S100A3and tumor was few compared to other members of thefamily of calcium-binding S100A.The affinity of S100A3can be considered as azinc ion signaling proteins. S100A3expression may be involved in malignanttransformation in the absence of early breast cells. Whether S100A3and HMGA1play an important role in CRC?
Cantharides are commonly known as Meloidae spot lytta insects. Cantharidinatewas a special effect for primary liver cancer. Cantharidinate was used more and morewidely. It was also gradually in-depth study. In recent years, study of cantharidinatemainly focused on the synthesis, biological functions, toxicity and physiologicalaspects in the United States and European countries. Anticancer mechanisms,pharmacology and applied research of cantharidinate were more in our country. Butthe cantharidinate for prevention and treatment of CRC had not been reported.
This study investigated the preventive and therapeutic effects of cantharidinate onhuman colorectal cancer both in vivo and in vitro. In addition, the mechanismsinvolved in origination and development of renal interstitial fibrosis also beenapproached. The main research contents is composed of①the relationship ofHMGA1and S100A3may be linked and investigated the role of HMGA1and S100A3in human CRC②the role of cantharidinate are observed for CRC③Theinhibition role and effect of cantharidinate are investigated for HMGA1and S100A3gene in human colorectal cancer.④The effect of cantharidinate is analyzed byRaman spectra.
Main results were as follows:
1. The protein expression of HMGA1and S100A3was significantly increasedin cancer tissues compared with the adjacent tissues.
2. The expression of S100A3and HMGA1may be correlated in CRC.
3. Immunohistochemistry and Western blot results confirmed that theexpression of HMGA1and S100A3was significantly increased in cancer tissuecompared with adjacent tissues (P <0.05and P <0.01).
4. After intervention of cantharidinate, Cell cycle occurs more obvious changesin colorectal cancer.The expression of HMGA1and S100A3decreased gradually(P<0.05). Its protein structure also improved after intervention of cantharidinatethrough Raman spectra.Conclusions were as follows:
1. S100A3and HMGA1play an important role in colorectal cancer.
2. Cantharidinate is similar with chemotherapy, it can reduce the gene andprotein expression of S100A3and HMGA1in tumor cells and improve cycle.
引文
[1] Herszényi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors.Eur Rev Med Pharmacol Sci [J].2010,14(4):249-58.
[2] Emmons KM, Burns White K, Benz EJ. Development of an integrated approachto cancer disparities: one cancer center's experience. Cancer EpidemiolBiomarkers Prev [J].2007,16(11):2186-92.
[3]佘金文,李铁钢.益生菌调节结直肠癌术后肠道粘膜免疫功能紊乱的临床研究进展[J].中国现代医药杂志,10(3):122-124.
[4] Sereda MJ. Purines2010: Adenine Nucleosides and Nucleotides inBiomedicine [J]. IDrugs.2010,13(8):534-8.
[5]周晓东，吕农华.结直肠癌的流行病学研究现状[J].现代消化及介入诊疗,11(3):149-151.
[6]刘启志,傅传刚. Ｋ-ras基因与结直肠癌靶向治疗的研究现状[J].结直肠肛门外科,2012,18(1):63-66.
[7] Cammarota R, Bertolini V, Pennesi G, et al. The tumor microenvironment ofcolorectal cancer: stromal TLR-4expression as a potential prognostic marker[J]. J Transl Med.2010,8(8):112.
[8] Beauchemin N. The colorectal tumor microenvironment: the next decade[J].Cancer Microenviron.2011,4(2):181-5.
[9] Khanna C, Hunter K. Modeling metastasis in vivo [J]. Carcinogenesis.2005,26(3):513-23.
[10] Dong-Mei Li, Jun Zhang, Wen-Mei Li, et al. MAWBP and MAWD inhibitproliferation and invasion in gastric cancer [J]. World J Gastroenterol.2013,19(18):2781–2792.
[11] van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment:molecular insights, antitumor effects, and clinical utility[J]. Oncologist.2006,11(4):397-408.
[12] Katz LH, Li Y, Chen JS, Mu oz NM, et al. Targeting TGF-β signaling incancer [J]. Expert Opin Ther Targets.2013,17(7):743-60.
[13] Hristov AC, Cope L, Di Cello F, et al. HMGA1correlates with advanced tumorgrade and decreased survival in pancreatic ductal adenocarcinoma [J]. ModPathol.2010,23(1):98-104.
[14] Radfar S, Martin H, Tilkin-Mariame AF. Tumor escape mechanism involvingFas and Fas-L molecules in human colorectal tumors [J]. Gastroenterol ClinBiol.2000,24(12):1191-6.
[15] Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumorprogression in colorectal cancer by inhibition of IL-6trans-signaling [J].Immunity.2004,21(4):491-501.
[16] Harpio R, Einarsson R. S100proteins as cancer biomarkers with focus onS100B in malignant melanoma [J]. Clin Biochem.2004,37(7):512-8.
[17] Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer:reassessing the target [J]. Cancer Res.2012,72(8):1909-14.
[18] Bloland P, Simone P, Burkholder B, et al. The role of public health institutionsin global health system strengthening efforts: the US CDC's perspective [J].PLoS Med.2012,9(4): e1001199.
[19] Min Zhao, Jingchun Sun, Zhongming Zhao, et al. TSGene: a web resource fortumor suppressor genes [J]. Nucleic Acids Res.2013,41(D1): D970–D976.
[20] Glinsky GV, Krones-Herzig A, Glinskii AB. Malignancy-associated regions oftranscriptional activation: gene expression profiling identifies commonchromosomal regions of a recurrent transcriptional activation in human prostate,breast, ovarian, and colorectal cancers [J]. Neoplasia.2003,5(3):218-28.
[21] Van de Ven WJ. Genetic basis of uterine leiomyoma: involvement of highmobility group protein genes [J]. Eur J Obstet Gynecol Reprod Biol.1998,81(2):289-93.
[22] Dou Y, Song X, Liu Y, et al. The H1phosphorylation state regulates expressionof CDC2and other genes in response to starvation in Tetrahymena thermophila[J]. Mol Cell Biol.2005,25(10):3914-22.
[23]侯春晖，黄建，张树冰，等. H MG l/Z和H MG14/17与人公珠蛋白基因启动子D N A的相互作用[J].科学通报,2002,47(14):1079-1082.
[24] Ge H, Roeder RG. The high mobility group protein HMG1can reversihlyinhibit classII gene transcription by interaction with the TATA-binding protein[J]. JBC,1994,269(25):17136-17140.
[25]徐佳，刘志锋，姜勇.高迁移率族蛋白与真核基因表达调控[J].生物化学与生物物理进展,2005,32(5):397-402.
[26] Aravind L, Landsman D. AT-hook motifs identified in a wide variety of DNA-binding proteins [J]. Nucleic Acids Res.1998,26(19):4413-21.
[27] Shimahara H, Hirano T, Ohya K, et al. Nucleosome structural changes inducedby binding of non-histone chromosomal proteins HMGN1and HMGN2[J].FEBS Open Bio.2013,28(3):184–191.
[28]李小凤，夏云.高速泳动族蛋白1的致炎症作用机制[J].生命的化学,2012,32(3):236-241.
[29] Lonskaya I, Potaman VN, Shlyakhtenko LS, et al. Regulation of poly(ADP-ribose) polymerase-1by DNA structure-specific binding [J].J Biol Chem2005,280(17):17076-17083.
[30]肖湘文，周建林，周畅.高迁移率族蛋白[J].细胞生物学杂志,2006,28(4):501-506.
[31] Ner SS, Travers AA. HMG-D, the Drosophila melanogaster homologue ofHMG1protein, is associated with early embryonic chromatin in the absence ofhistone H1[J]. EMBO J.1994,13(8):1817-22.
[32] Pallier C, Scaffidi P, Chopineau-Proust S, et al. Association of chromatinproteins high mobility group box (HMGB)1and HMGB2with mitoticchromosomes [J]. Mol Biol Cell.2003,14(8):3414-26.
[33]董小倩，冯云.高迁移率族蛋白N家族抗肿瘤活性的研究进展[J].国际口腔医学杂志,2013,40(3):364-367.
[34] Braet C, Stephan H, Dobbie IM, et al. Mobility and distribution of replicationprotein A in living cells using fluorescence correlation spectroscopy [J]. Exp MolPathol.2007,82(2):156-62.
[35] Kugler JE, Deng T, Bustin M. The HMGN family of chromatin-bindingproteins: dynamic modulators of epigenetic processes [J]. Biochim BiophysActa.2012,1819(7):652-6.
[36] West KL, Castellini MA, Duncan MK, et al. Chromosomal proteins HMGN3aand HMGN3b regulate the expression of glycine transporter1[J].Mol Cell Biol.2004,24(9):3747-56.
[37] Hassa PO, Haenni SS, Elser M, et al. Nuclear ADP-ribosylation reactions inmammalian cells: where are we today and where are we going?[J]. MicrobiolMol Biol Rev.2006,70(3):789-829.
[38] Elenkov I, Pelovsky P, Ugrinova I, et al. The DNA binding and bendingactivities of truncated tail-less HMGB1protein are differentially affected byLys-2and Lys-81residues and their acetylation [J]. Int J Biol Sci.2011,7(6):691-9.
[39] Zhang Q, Wang Y. HMG modifications and nuclear function [J]. BiochimBiophys Acta.2010,1799(1-2):28-36.
[40] Pogna EA, Clayton AL, Mahadevan LC. Signalling to chromatin through post-translational modifications of HMGN [J]. Biochim Biophys Acta.2010,1799(1-2):93-100.
[41] Beitzel B, Bushman F. Construction and analysis of cells lacking the HMGAgene family [J]. Nucleic Acids Res.2003,31(17):5025-32.
[42] Hu X, Jiang H, Bai Q, et al. Increased serum HMGB1is related to the severityof coronary artery stenosis [J]. Clin Chim Acta.2009,406(1-2):139-42.
[43]彭芳，赵力，王国付，等. HMGA1在肺癌中的表达及临床病理学意义[J].健康研究,2013,33(2):97-102.
[44] Esposito F, Tornincasa M, Federico A, et al. High-mobility group A1proteininhibits p53-mediated intrinsic apoptosis by interacting with Bcl-2atmitochondria [J]. Cell Death Dis.2012,30(3): e383.
[45] Biasco L, Baricordi C, Aiuti A. Retroviral integrations in gene therapy trials[J].Mol Ther.2012,20(4):709-16.
[46] Bushman FD. Retroviral integration and human gene therapy [J]. J Clin Invest.2007,117(8):2083-6.
[47] Brown MS, Goldstein JL. Scientific side trips: six excursions from the beatenpath [J]. J Biol Chem.2012,287(27):22418-35.
[48] Preston SL, Alison MR, Forbes SJ, et al. The new stem cell biology: something foreveryone [J]. Mol Pathol.2003,56(2):86-96.
[49]颜丙超，范月超. MicroRNA let-7与HMGA2在垂体腺瘤中的相互关系[J].国际神经病学神经外科学杂志,2012,39(6):576-580.
[50]杨霞，李国华. HMGA1与肿瘤的研究进展[J].江西医药,2009,44(1):79-82.
[51] Dement GA, Maloney SC, Reeves R. Nuclear HMGA1nonhistone chromatinproteins directly influence mitochondrial transcription, maintenance, and function[J]. Exp Cell Res.2007,313(1):77-87.
[52] Donald LJ, Hosfield DJ, Cuvelier SL, et al. Mass spectrometric study of theEscherichia coli repressor proteins, Ic1R and Gc1R, and their complexes withDNA [J]. Protein Sci.2001,10(7):1370-80.
[53] Tugarinov V, Hwang PM, Kay LE. Nuclear magnetic resonance spectroscopyof high-molecular-weight proteins [J]. Annu Rev Biochem.2004,73:107-46.
[54] Zhang Q, Wang Y. HMG Modifications and Nuclear Function [J]. BiochimBiophys Acta.2010,1799(1-2):28-36.
[55] Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of thehuman genome [J]. Nature.2001,409(6822):860-921.
[56] Popescu NC, King CR, Kraus MH. Localization of the human erbB-2gene onnormal and rearranged chromosomes17to bands q12-21.32[J]. Genomics.1989,4(3):362-6.
[57] Gurova K. New hopes from old drugs: revisiting DNA-binding small moleculesas anticancer agents [J]. Future Oncol.2009,5(10):1685-704.
[58] Fan H, Guo H, Zhang IY, et al. The different HMGA1expression of totalpopulation of glioblastoma cell line U251and glioma stem cells isolated fromU251[J]. Brain Res.2011,1384:9-14.
[59] Vervoort SJ, van Boxtel R, Coffer PJ. The role of SRY-related HMG boxtranscription factor4(SOX4) in tumorigenesis and metastasis: friend or foe?[J].Oncogene.2013,32(29):3397-409.
[60] Coppotelli G, Mughal N, Callegari S, et al. The Epstein-Barr virus nuclear antigen-1reprograms transcription by mimicry of high mobility group A proteins [J]. NucleicAcids Res.2013,41(5):2950-62.
[61] Goldfine ID. The insulin receptor: molecular biology and transmembranesignaling [J]. Endocr Rev.1987,8(3):235-55.
[62] Vogel B, L schberger A, Sauer M, et al. Cross-linking of DNA throughHMGA1suggests a DNA scaffold [J]. Nucleic Acids Res.2011,39(16):7124-33.
[63] Edberg DD, Adkins JN, Springer DL, et al. Dynamic and differential in vivomodifications of the isoform HMGA1a and HMGA1b chromatin proteins [J]. J BiolChem.2005,280(10):8961-73.
[64] Crevel G, Huikeshoven H, Cotterill S. Df31is a novel nuclear protein involvedin chromatin structure in Drosophila melanogaster [J]. J Cell Sci.2001,114(Pt1):37-47.
[65] Smith EM, Proud CG. cdc2-cyclin B regulates eEF2kinase activity in a cellcycle-and amino acid-dependent manner [J]. EMBO J.2008,27(7):1005-16.
[66] Palmieri D, D'Angelo D, Valentino T, et al. Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis [J].Oncogene.2012,31(34):3857-65.
[67] Lemke I, Rogalla P, Bullerdiek J. A novel LPP fusion gene indicates the crucialrole of truncated LPP proteins in lipomas and pulmonary chondroidhamartomas [J]. Cytogenet Cell Genet.2001,95(3-4):153-6.
[68]张小茜,全先庆,单雷,等.高迁移率族蛋白A的特征及其在转录中的调控[J].生命的化学,2006,26(5):414-417.
[69] Sgarra R, Lee J, Tessari MA, et al. The AT-hook of the chromatin architecturaltranscription factor high mobility group A1a is arginine-methylated by proteinarginine methyltransferase6[J]. J Biol Chem.2006,281(7):3764-72.
[70] Sgarra R, Maurizio E, Zammitti S, et al. Macroscopic differences in HMGAoncoproteins post-translational modifications: C-terminal phosphorylation ofHMGA2affects its DNA binding properties [J]. J Proteome Res.2009,8(6):2978-89.
[71] García-Heras F, Abellón-Ruiz J, Murillo FJ, et al. High-mobility-group a-likeCarD binds to a DNA site optimized for affinity and position and to RNApolymerase to regulate a light-inducible promoter in Myxococcus xanthus[J]. JBacteriol.2013,195(2):378-88.
[72] Panne D, Maniatis T, Harrison SC. An atomic model of the interferon-betaenhanceosome [J]. Cell.2007,129(6):1111-23.
[73] Reményi A, Lins K, Nissen LJ, et al. Crystal structure of a POU/HMG/DNAternary complex suggests differential assembly of Oct4and Sox2on twoenhancers [J]. Genes Dev.2003,17(16):2048-59.
[74] Mao L, Wertzler KJ, Maloney SC, et al. HMGA1levels influencemitochondrial function and mitochondrial DNA repair efficiency [J]. Mol CellBiol.2009,9(20):5426-40.
[75] Jayaraman L, Moorthy NC, Murthy KG, et al. High mobility group protein-1(HMG-1) is a unique activator of p53[J]. Genes Dev.1998,12(4):462-72.
[76] Singh BN, Zhang G, Hwa YL, et al. Nonhistone protein acetylation as cancertherapy targets[J]. Expert Rev Anticancer Ther.2010,10(6):935-54.
[77] Mukherjee A, Melnattur KV, Zhang M, et al. Maternal expression and functionof the Drosophila sox gene Dichaete during oogenesis [J]. Dev Dyn.2006,235(10):2828-35.
[78] Baron RM, Lopez-Guzman S, Riascos DF, et al. Distamycin A inhibitsHMGA1-binding to the P-selectin promoter and attenuates lung and liverinflammation during murine endotoxemia [J]. PLoS One.2010,5(5): e10656.
[79] Dekker J, Marti-Renom MA, Mirny LA. Exploring the three-dimensionalorganization of genomes: interpreting chromatin interaction data [J]. Nat RevGenet.2013,14(6):390-403.
[80] Baltz JL, Filman DJ, Ciustea M, et al. The crystal structure of PF-8, the DNApolymerase accessory subunit from Kaposi's sarcoma-associated herpesvirus [J].J Virol.2009,83(23):12215-28.
[81] Bustin M. Regulation of DNA-dependent activities by the functional motifs ofthe high-mobility-group chromosomal proteins [J]. Mol Cell Biol.1999,19(8):5237-46.
[82] Dement GA, Treff NR, Magnuson NS, et al. Dynamic mitochondriallocalization of nuclear transcription factor HMGA1[J]. Exp Cell Res.2005,307(2):388-401.
[83] Di Cello F, Shin J, Harbom K, et al. Knockdown of HMGA1inhibits humanbreast cancer cell growth and metastasis in immunodeficient mice [J]. BiochemBiophys Res Commun.2013,434(1):70-4.
[84] Miranda TB, Webb KJ, Edberg DD, et al. Protein arginine methyltransferase6specifically methylates the nonhistone chromatin protein HMGA1a [J].Biochem Biophys Res Commun.2005,336(3):831-5.
[85] Falvo JV, Lin CH, Tsytsykova AV, et al. A dimer-specific function of thetranscription factor NFATp [J]. Proc Natl Acad Sci U S A.2008,105(50):19637-42.
[86] Nezhad MH, Drieschner N, Helms S, et al.6p21rearrangements in uterineleiomyomas targeting HMGA1[J]. Cancer Genet Cytogenet.2010,203(2):247-52.
[87] Chiefari E1, Arcidiacono B1, Possidente K1, et al. Transcriptional Regulationof the HMGA1Gene by Octamer-Binding Proteins Oct-1and Oct-2[J]. PLoSOne.2013,8(12):e83969.
[88] Chiappetta G, Avantaggiato V, Visconti R, et al. High level expression of theHMGI (Y) gene during embryonic development [J]. Oncogene.1996,13(11):2439-46.
[89] Catez F, Yang H, Tracey KJ, et al. Network of dynamic interactions betweenhistone H1and high-mobility-group proteins in chromatin [J]. Mol Cell Biol.2004,24(10):4321-8.
[90] Akaboshi S, Watanabe S, Hino Y, et al. HMGA1is induced by Wnt/beta-catenin pathway and maintains cell proliferation in gastric cancer [J]. Am JPathol.2009,175(4):1675-85.
[91] Yoshida Y, Shibata T, Kokubu A, et al. Mutations of the epidermal growthfactor receptor gene in atypical adenomatous hyperplasia andbronchioloalveolar carcinoma of the lung [J]. Lung Cancer.2005,50(1):1-8.
[92]许永华，李长贤，陈杰，等.高迁移率族蛋白A1（HMGA1）在肝细胞癌中的表达及临床意义[J].南京医科大学学报(自然科学版),2010,30(3):304-308.
[93] Mansueto G, Forzati F, Ferraro A, et al. Identification of a New Pathway forTumor Progression: MicroRNA-181b Up-Regulation and CBX7Down-Regulation by HMGA1Protein [J]. Genes Cancer.2010,1(3):210-24.
[94] Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer:new insights into mechanisms, progression, and target identification [J]. J ClinOncol.2006,24(35):5552-64.
[95] Takeuchi I, Takaha N, Nakamura T, et al. High mobility group protein AT-hook1(HMGA1) is associated with the development of androgenindependence in prostate cancer cells [J]. Prostate.2012,72(10):1124-32.
[96] Angeloni C, Pirola L, Vauzour D, et al. Dietary polyphenols and their effects oncell biochemistry and pathophysiology [J]. Oxid Med Cell Longev.2012,2012:583901
[97] Mao L, Wertzler KJ, Maloney SC, et al. HMGA1levels influencemitochondrial function and mitochondrial DNA repair efficiency [J]. Mol CellBiol.2009,29(20):5426-40.
[98] Hillion J, Smail SS, Di Cello F, et al. The HMGA1-COX-2axis: a keymolecular pathway and potential target in pancreatic adenocarcinoma[J].Pancreatology.2012,12(4):372-9.
[99] Leroux-Roels I, Leroux-Roels G, Ofori-Anyinam O, et al. Evaluation of thesafety and immunogenicity of two antigen concentrations of theMtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults [J]. Clin Vaccine Immunol.2010,17(11):1763-71.
[100]Venkatesan N, Krishnakumar S, Deepa PR, et al. Molecular deregulationinduced by silencing of the high mobility group protein A2gene inretinoblastoma cells [J]. Mol Vis.2012,18:2420-37.
[101]Shah SN, Cope L, Poh W, et al. HMGA1: a master regulator of tumorprogression in triple-negative breast cancer cells [J]. PLoS One.2013,8(5):e63419.
[102]Kang MI, Baker AR, Dextras CR, et al. Targeting of Noncanonical Wnt5aSignaling by AP-1Blocker Dominant-Negative Jun When It Inhibits SkinCarcinogenesis [J]. Genes Cancer.2012,3(1):37-50.
[103]Wang C, Chen T, Zhang J, et al. The E3ubiquitin ligase Nrdp1'preferentially'promotes TLR-mediated production of type I interferon [J]. Nat Immunol.2009,10(7):744-52.
[104]Burrows AC, Prokop J, Summers MK. Skp1-Cul1-F-box ubiquitin ligase(SCF(βTrCP))-mediated destruction of the ubiquitin-specific protease USP37during G2-phase promotes mitotic entry [J]. J Biol Chem.2012,287(46):39021-9.
[105]Dhar A, Hu J, Reeves R, Resar LM, et al. Dominant-negative c-Jun (TAM67)target genes: HMGA1is required for tumor promoter-induced transformation[J]. Oncogene.2004,23(25):4466-76.
[106]Erkan M, Reiser-Erkan C, Michalski CW, et al. Tumor microenvironment andprogression of pancreatic cancer [J]. Exp Oncol.2010,32(3):128-31.
[107]Reuter S, Gupta SC, Chaturvedi MM, et al. Oxidative stress, inflammation, andcancer: how are they linked?[J]. Free Radic Biol Med.2010,49(11):1603-16.
[108]Lonkar P, Dedon PC. Reactive species and DNA damage in chronicinflammation: reconciling chemical mechanisms and biological fates [J]. Int JCancer.2011,128(9):1999-2009.
[109]Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervicalcancer [J]. Lancet.2007,370(9590):890-907.
[110]Zhu S, Wu H, Wu F, et al. MicroRNA-21targets tumor suppressor genes ininvasion and metastasis [J]. Cell Res.2008,18(3):350-9.
[111]Ryu CH, Park KY, Hou Y, et al. Gene therapy of multiple sclerosis usinginterferon β-secreting human bone marrow mesenchymal stem cells [J].Biomed Res Int.2013,2013:696738.
[112]Baldassarre G, Battista S, Belletti B, et al. Negative regulation of BRCA1geneexpression by HMGA1proteins accounts for the reduced BRCA1proteinlevels in sporadic breast carcinoma [J]. Mol Cell Biol.2003,23(7):2225-38.
[113]Wu J, Liu Z, Shao C, et al. HMGA2overexpression-induced ovarian surfaceepithelial transformation is mediated through regulation of EMT genes [J].Cancer Res.2011,71(2):349-59.
[114]Wang EL, Qian ZR, Rahman MM, et al. Increased expression of HMGA1correlates with tumour invasiveness and proliferation in human pituitaryadenomas [J]. Histopathology.2010,56(4):501-9.
[115]Scala S, P.G., Fedele M, Chiappetta G, et al.Adenovirus-mediated suppressionof HMGI(Y) protein synthesis as potential therapy of human malignantneoplasias [J]. Proc Natl Acad Sci USA,2000,97(8): p.4256-4261
[116]Trapasso F, S.M., Cesari R, Yendamuri S, et al. Therapy of human pancreaticcarcinoma based on suppression of HMGA1protein synthesis in preclinicalmodels [J]. Cancer Gene Ther,2004.11(9): p.633-641.
[117]Liau SS, Jazag A, Ito K, et al. Overexpression of HMGA1promotes anoikisresistance and constitutive Akt activation in pancreatic adenocarcinoma cells[J]. Br J Cancer.2007,96(6):993-1000.
[118]Reeves R, E.D., Li Y.Architectural transcription factor HMG1(Y) promotestumour progression and mesenchymal transition of human epithelial cells [J].Mol Cell Biol,2001.21: p.575-584.
[119]Wieghaus KA, Gianchandani EP, Neal RA, et al. Phthalimide neovascularfactor1(PNF1) modulates MT1-MMP activity in human microvascularendothelial cells [J]. Biotechnol Bioeng.2009,103(4):796-807.
[120]J rvel inen H, Sainio A, Koulu M, et al. Extracellular matrix molecules:potential targets in pharmacotherapy [J]. Pharmacol Rev.2009,61(2):198-223.
[121]E, G.F.a.R. Integrin signaling. Science,1999.285: p.1028-1032.
[122]Salmans ML, Zhao F, Andersen B. The estrogen-regulated anterior gradient2(AGR2) protein in breast cancer: a potential drug target and biomarker [J].Breast Cancer Res.2013,24;15(2):204.
[123]Serini G, Bochaton-Piallat ML, Ropraz P, et al. Tumor growth modeling fromthe perspective of multiphase porous media mechanics [J]. Mol Cell Biomech.2012,9(3):193-212.
[124]Hunter SE, Jung D, Di Giulio RT, et al. The QPCR assay for analysis ofmitochondrial DNA damage, repair, and relative copy number [J]. Methods.2010,51(4):444-51.
[125]Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview ofresistance to systemic therapy in patients with breast cancer [J]. Adv Exp MedBiol.2007,608:1-22.
[126]Geng M, Wang L, Li P. Correlation between chemosensitivity to anticancerdrugs and Bcl-2expression in gastric cancer [J]. Int J Clin Exp Pathol.2013,6(11):2554-9.
[127]Gustafson DH, Shaw BR, Isham A, et al. Explicating an evidence-based,theoretically informed, mobile technology-based system to improve outcomesfor people in recovery for alcohol dependence [J]. Subst Use Misuse.2011,46(1):96-111.
[128]Fernandez Tde S, de Souza Fernandez C, Mencalha AL. Human inducedpluripotent stem cells from basic research to potential clinical applications incancer [J]. Biomed Res Int.2013;2013:430290.
[129]Chen CZ, Schaffert S, Fragoso R, et al. Regulation of immune responses andtolerance: the microRNA perspective [J]. Immunol Rev.2013,253(1):112-28.
[130]Que JU, Casey SW, Hentges DJ. Factors responsible for increasedsusceptibility of mice to intestinal colonization after treatment withstreptomycin [J]. Infect Immun.1986,53(1):116-23.
[131]Jeong SH, Kang D, Lim MW, et al. Risk assessment of growth hormones andantimicrobial residues in meat [J]. Toxicol Res.2010,26(4):301-13.
[132]Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancerprogression: biology and implications for treatment [J]. Breast Cancer Res.2011,13(6):227.
[133]Liau SS, A.S.a.W.E.Lentivirus-mediated RNA interference of HMGA1promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma [J]. JGastrointest Surg,2006.10(9): p.1254-1262.
[134]Liau SS, Ashley SW, Whang EE. Lentivirus-mediated RNA interference ofHMGA1promotes chemosensitivity to gemcitabine in pancreaticadenocarcinoma [J]. J Gastrointest Surg.2006,10(9):1254-62.
[135]Xu M, Sharma P, Pan S, et al. Core promoter-selective function of HMGA1and Mediator in Initiator-dependent transcription [J]. Genes Dev.2011,25(23):2513-24.
[136]Zhang Q, Wang Y. HMG modifications and nuclear function [J]. BiochimBiophys Acta.2010,1799(1-2):28-36.
[137]L, R.R.a.B. HMGI/Y proteins: flexible regulators of transcription andchromatin structure [J]. Biochim Biophys Acta,2001,1519(1-2): p.13-29.
[138]Pierantoni GM, Rinaldo C, Esposito F, et al. Retraction: High Mobility GroupA1(HMGA1) proteins interact with p53and inhibit its apoptotic activity [J].Cell Death Differ.2014,21(3):503.
[139]Pierantoni GM, Rinaldo C, Mottolese M, et al. High-mobility group A1inhibitsp53by cytoplasmic relocalization of its proapoptotic activator HIPK2[J]. JClin Invest.2007,117(3):693-702.
[140]Wajed SA, Laird PW, DeMeester TR. DNA methylation: an alternativepathway to cancer [J]. Ann Surg.2001,234(1):10-20.
[141]Veschi V, Petroni M, Cardinali B, et al. Galectin-3impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3inneuroblastoma cells [J]. PLoS One.2012,7(11): e49139.
[142]Adair JE, K.Y., Dement GA, Smerdon MJ, et al. Inhibition of nucleotideexcision repair by high mobility group protein HMGA1[J]. J Biol Chem,2005.280(37): p.32184-32192.
[143]Dement GA, T.N., Magnuson NS, Franceschi V, et al. Dynamic mitochondriallocalization of nuclear transcription factor HMGA1[J]. Exp Cell Res.,2005,307(2): p.388-401.
[144]1443. Dement GA, M.S., Reeves R. Nuclear HMGA1nonhistone chromatinproteins directly influence mitochondrial transcription, maitenance, andfunction [J]. Exp Cell Res.,2007,313(1): p.77-87.
[145]Treff NR, D.G., Adair JE, Britt RL, et al. Human KIT ligand promoter ispositively regulated by HMGA1in breast and ovarian cancer cells [J].Oncogene,2004,23(52): p.8557-8562.
[146]Lenard NR, Berthoud HR. Central and peripheral regulation of food intake andphysical activity: pathways and genes [J]. Obesity (Silver Spring).2008,16Suppl3: S11-22.
[147]Hock R, Furusawa T, Ueda T, et al. HMG chromosomal proteins indevelopment and disease [J]. Trends Cell Biol.2007,17(2):72-9.
[148]Moskwa P, Buffa FM, Pan Y, et al. miR-182-mediated downregulation ofBRCA1impacts DNA repair and sensitivity to PARP inhibitors [J]. Mol Cell.2011,41(2):210-20.
[149]Panda AC, Grammatikakis I, Yoon JH, et al. Posttranscriptional regulation ofinsulin family ligands and receptors [J]. Int J Mol Sci.2013,14(9):19202-29.
[150]Diana F, S.R., Manfioletti G, Rustighi A, et al. A link between apoptosis anddegree of phosphorylation of high mobility group A1a protein in leukemic cells.J Biol Chem.,2001,276(14): p.11354-11361.
[151]Kleindienst A, Harvey HB, Rice AC, et al. Intraventricular infusion of theneurotrophic protein S100B improves cognitive recovery after fluid percussioninjury in the rat[J]. J Neurotrauma.2004,21(5):541-7.
[152]Yanyi C, Shenghui X, Yubin Z, et al. Calciomics: prediction and analysis ofEF-hand calcium binding proteins by protein engineering [J]. Sci China Chem.2010,53(1):52-60.
[153]Keijser S, Missotten GS, Bonfrer JM, et al. Immunophenotypic markers todifferentiate between benign and malignant melanocytic lesions [J]. Br JOphthalmol.2006,90(2):213-7.
[154]Moroz OV, Burkitt W, Wittkowski H, et al. Both Ca2+and Zn2+are essentialfor S100A12protein oligomerization and function [J]. BMC Biochem.2009,3.10:11.
[155]Takizawa T, Takizawa T, Arai S, et al. Ultrastructural localization of S100A3,a cysteine-rich, calcium binding protein, in human scalp hair shafts revealed byrapid-freezing immunocytochemistry [J]. J Histochem Cytochem.1999,47(4):525-32.
[156]Ilg EC, Sch fer BW, Heizmann CW. Expression pattern of S100calcium-binding proteins in human tumors [J]. Int J Cancer.1996,68(3):325-32.
[157]Webb M, Emberley ED, Lizardo M, et al. Expression analysis of the mouseS100A7/psoriasin gene in skin inflammation and mammary tumorigenesis [J].BMC Cancer.2005,17，5:17.
[158]Goldstone R, Itzkowitz S, Harpaz N, et al. Dysplasia is more common in thedistal than proximal colon in ulcerative colitis surveillance [J]. Inflamm BowelDis.2012,18(5):832-7.
[159]Ia tski NA, Gelazoniia RV, Khatelishvili VM. Surgical treatment of cancer ofthe colon involving adjacent organs and tissue [J]. Vestn Khir Im I I Grek.1988,140(1):58-60.
[160]Aparo S, Goel S. Evolvement of the treatment paradigm for metastatic coloncancer. From chemotherapy to targeted therapy [J]. Crit Rev Oncol Hematol.2012,83(1):47-58.
[161]Blagosklonny MV. Common drugs and treatments for cancer and age-relateddiseases: revitalizing answers to NCI's provocative questions [J]. Oncotarget.2012,3(12):1711-24.
[162]Daniels AL, Van Slambrouck S, Lee RK, et al. Effects of extracts from twoNative American plants on proliferation of human breast and colon cancer celllines in vitro [J]. Oncol Rep.2006,15(5):1327-31.
[163]曾芳,李媛.大黄有效化学成分及其药理作用[J].当代医学,2013,19(12):149.
[164]姜晓峰,甄永苏.大黄素逆转肿瘤细胞多药抗药性的作用[J].药学学报,1999,34(3)∶164-167.
[165]Chun-Guang W, Jun-Qing Y, Bei-Zhong L, et al. Anti-tumor activity ofemodin against human chronic myelocytic leukemia K562cell lines in vitroand in vivo [J]. Eur J Pharmacol.2010,627(1-3):33-41.
[166]吕盈盈,钱家鸣,邱辉忠.大黄素对结直肠癌血管内皮生长因子受体的影响及对结直肠癌抑制作用的研究[J].中国中西医结合消化杂志,2005,13(5):310-313.
[167]李进，冯成强，张文生.冬虫夏草研究回顾与展望[J].农业资源与环境科学，2008，24(2):382–384.
[168]雷万生,谢联斌,陈和平.冬虫夏草的研究概况[J].海军医学杂志,2006,27(3):262-269.
[169]黄浩,王航,罗荣城.冬虫夏草提取液抑制结直肠癌细胞增殖的研究[J].中药材,2007,30(3):310-313.
[170]Huang H, Wang H, Luo RC. Inhibitory effects of cordyceps extract on growthof colon cancer cells [J]. Zhong Yao Cai.2007,30(3):310-3.
[171]黄赞松，周喜汉.苦参素药理和抗肿瘤作用研究[J].医学综述，2005，15(11):1701-1703.
[172]Lu LG, Zeng MD, Mao YM, et al. Oxymatrine therapy for chronic hepatitis B:a randomized double-blind and placebo-controlled multi-center trial [J]. WorldJ Gastroenterol.2003,9(11):2480-3.
[173]Olaku O, White JD. Herbal therapy use by cancer patients: a literature reviewon case reports [J]. Eur J Cancer.2011,47(4):508-14.
[174]阳巍，廖端芳，庹勤慧.姜黄素抗动脉粥样硬化研究进展[J].国际病理科学与临床杂志,2012,32(1):55-58.
[175]郑玉强，邓立普.姜黄素药理作用研究进展[J].辽宁中医药大学学报,2012,11(2):212-214.
[176]余美荣，蒋福升，丁志山.姜黄素的研究进展[J].中草药，2009，40(5)：828-831.
[177]任贻军，高逢喜.黄连素的研究进展[J].辽宁中医药大学学报,2009,11(1):50-51.
[178]李晓苗，王海军，李源，等.黄连素降糖作用机制研究进展[J].陕西医学杂志,2012,41(11):1547-1549.
[179]郭学敏,洪永福,周桌轮.毛蓖属植物化学成分研究概况[J].中草药,1995,26(10):550-551.
[180]王海燕,赵雪花,何丽娅.黄连素抗癌作用的分子机制[J].中国药房,2007,18(3):221-223.
[181]陆宁,王邦茂,黄迺侠,等.黄连素对脱氧胆酸诱导的人结直肠癌细胞株增殖抑制作用及机制[J].中华消化医学,2006,26(9):632-633.
[182]乐崇熙，楼之岑.中药天花粉及其类似品德鉴别研究[J].药学学报，1979,14(11):641-651.
[183]王海英，刘旭.东天花粉抗肿瘤研究进展[J].国医论坛,2005,20(1):54–55.
[184]林国庆,邵靖宇.天花粉蛋白研究新进展[J].科技通报,1996,12(2):122-125.
[185]王英俊,付莉,华海婴.黄芩苷诱导结直肠癌细胞株SW21116凋亡的研究[J].中医研究,2007,20(6):22-23.
[186]李森林,肖文海,黄岩.斑蝥的现代药理研究和临床应用[J].中国社区医师(综合版).2007,169(9):16.
[187]李森朋，谭学杰，赵云雪，等.脱氢脱甲基斑蝥酸银配聚物体内外抗肿瘤活性研究[J].中国药理学通报.2013，(12):1774-1775.
[188]姚燕丹，林少芒.去甲斑蝥素的研究进展及其与乳腺癌的关系[J].中国医药导刊,2005,7(1):58.
[189]江励华，王明艳.斑蝥的研究[J].医药导报,2004,23(6):385.
[190]安中原,王正,赵越.斑蝥素及其衍生物的抗肿瘤研究进展[J].亚太传统医药,2009,5(1):128-130.
[191]191.尹璇,陈志伟.斑蝥素及其药理作用研究进展[J].生命科学仪器,2009,7(3):3-6.
[192]Barrett TW, Peticolas WL, Robson RM. Laser Raman light-scatteringobservations of conformational changes in myosin induced by inorganic salts[J]. Biophys J.1978,23(3):349-58.
[193]龚,卢永凯,林素君,等.拉曼光谱技术在色谱分析检测中的应用[J].化学通报,2010,8:689-692.
[194]胡晓红,周金池.拉曼光谱的应用及其进展[J].分析仪器,2011,6:1-4.
[195]刘玲.激光拉曼光谱及其应用进展[J].山西大学学报(自然科学版),2001,24(3):279-282.
[196]王敏,俞帆,隆泉.激光拉曼光谱在蛋白质构象研究中的应用和进展[J].激光生物学报,2006,16(4):516-520.
[197]陆天虹.表面增强拉曼光谱及其在化学中的应用[J].腐蚀科学与防护技术,1995,7(2):102-107.
[198]Cardoso MM, Pe a IN, Roque AC. Antibody-conjugated nanoparticles fortherapeutic applications [J]. Curr Med Chem.2012,19(19):3103-27.
[199]Arias JL, López-Viota M, Ruiz MA, et al. Development of carbonyliron/ethylcellulose core/shell nanoparticles for biomedical applications [J]. Int JPharm.2007,339(1-2):237-45.
[200]Ong YH, Lim M, Liu Q. Comparison of principal component analysis andbiochemical component analysis in Raman spectroscopy for the discriminationof apoptosis and necrosis in K562leukemia cells [J]. Opt Express.2012,20(20):22158-71.
[201]Pharoah PD, Guilford P, Caldas C, et al. Incidence of gastric cancer and breastcancer in CDH1(E-cadherin) mutation carriers from hereditary diffuse gastriccancer families [J]. Gastroenterology.2001,12(6):1348-53.
[202]de la Torre NG, Buley I, Wass JA, et al. Angiogenesis and lymphangiogenesis inthyroid proliferative lesions: relationship to type and tumour behavior [J].Endocr Relat Cancer.2006,13(3):931-44.
[203]Huang Z, McWilliams A, Lui H, et al. Near-infrared Raman spectroscopy foroptical diagnosis of lung cancer [J]. Int J Cancer.2003,107(6):1047-52.
[204] Panikkanvalappil SR, Mackey MA, El-Sayed MA. Probing the uniquedehydration-induced structural modifications in cancer cell DNA using surfaceenhanced Raman spectroscopy [J]. J Am Chem Soc.2013,135(12):4815-21.
[205] Kendall C, Stone N, Shepherd N, et al. Raman spectroscopy, a potential tool forthe objective identification and classification of neoplasia in Barrett'soesophagus [J]. J Pathol.2003,200(5):602-9.
[206]Amersi F, Agustin M, Ko CY. Colorectal cancer: epidemiology, risk factors,and health services [J]. Clin Colorectal Rectal Surg.2005,18(3):133-40.
[207]Kovoor PA, Hwang J. Treatment of resectable gastric cancer: current standardsof care [J]. Expert Rev Anticancer Ther.2009,9(1):135-42.
[208]Ioka T, Ishikawa H, Akedo I, et al. Study of Prevention of Colorectal Cancerthrough Lifestyle Modification: an Introduction to the Protocol [J]. Asian Pac JCancer Prev.2001,2(3):233-236.
[209]Choong MK, Tsafnat G. Genetic and epigenetic biomarkers of colorectalcancer [J]. Clin Gastroenterol Hepatol.2012,10(1):9-15.
[210]Yao R, Lopez-Beltran A, Maclennan GT, et al. Expression of S100proteinfamily members in the pathogenesis of bladder tumors [J]. Anticancer Res.2007,27(5A):3051-8.
[211]Wei JJ, Wu X, Peng Y, et al. Regulation of HMGA1expression by microRNA-296affects prostate cancer growth and invasion [J]. Clin Cancer Res.2011,17(6):1297-305.
[212] Manuell AL, Beligni MV, Elder JH, et al. Robust expression of a bioactivemammalian protein in Chlamydomonas chloroplast [J]. Plant Biotechnol J.2007,5(3):402-12.
[213]Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality,survival, and risk factors [J]. Clin Colorectal Rectal Surg.2009,22(4):191-7.
[214]Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous systeminduces a metastatic switch in primary breast cancer [J]. Cancer Res.2010,70(18):7042-52.
[215]Lloyd BH, Ruddell C, Rudland PS, et al. S100A3mRNA expression displaysan inverse correlation to breast cancer progression. Biochem Soc Trans1996,24(3):340.
[216]Koontongkaew S. The tumor microenvironment contribution to development,growth, invasion and metastasis of head and neck squamous cell carcinomas [J].J Cancer.2013,4(1):66-83.
[217]Camby I, Lefranc F, Titeca G, et al. Differential expression of S100calcium-binding proteins characterizes distinct clinical entities in both WHO grade IIand III astrocytic tumours [J]. Neuropathol Appl Neurobiol.2000,26(1):76-90.
[218]Ilg EC, Sch fer BW, Heizmann CW. Expression pattern of S100calcium-binding proteins in human tumors [J]. Int J Cancer.1996,68(3):325-32.
[219]Cao Z, Tanguay RL, McKenzie D, et al. Identification of a putative calcium-binding protein as a dioxin-responsive gene in zebrafish and rainbow trout[J].Aquat Toxicol.2003,63(3):271-82.
[220]Liotta L, Petricoin E. Molecular profiling of human cancer [J]. Nat Rev Genet.2000,1(1):48-56.
[221]Wang Z, Feng X, Liu X, et al. Involvement of potential pathways in malignanttransformation from oral leukoplakia to oral squamous cell carcinoma revealedby proteomic analysis [J]. BMC Genomics.2009,10:383.
[222] Morrison RD, Blobaum AL, Byers FW, et al. The role of aldehyde oxidaseand xanthine oxidase in the biotransformation of a novel negative allostericmodulator of metabotropic glutamate receptor subtype5[J]. Drug MetabDispos.2012,40(9):1834-45.
[223]Sarhadi VK, Wikman H, Salmenkivi K, et al. Increased expression of highmobility group A proteins in lung cancer [J]. J Pathol.2006,209(2):206-12.
[224]Dolde CE, Mukherjee M, Cho C, et al. HMG-I/Y in human breast cancer celllines [J]. Breast Cancer Res Treat.2002,71(3):181-91.
[225] Fedele M, Fidanza V, Battista S, et al. Haploinsufficiency of the Hmga1genecauses cardiac hypertrophy and myelo-lymphoproliferative disorders in mice[J]. Cancer Res.2006,66(5):2536-43.
[226].Pierantoni GM, Battista S, Pentimalli F, et al. A truncated HMGA1geneinduces proliferation of the3T3-L1pre-adipocytic cells: a model of humanlipomas [J]. Carcinogenesis.2003,24(12):1861-9.
[227]Groves P, Palczewska M.Cation binding properties of calretinin, an EF-handcalcium-binding protein [J]. Acta Biochim Pol.2001,48(1):113-9.
[2] Emmons KM, Burns White K, Benz EJ. Development of an integrated approachto cancer disparities: one cancer center's experience. Cancer EpidemiolBiomarkers Prev [J].2007,16(11):2186-92.
[3]佘金文,李铁钢.益生菌调节结直肠癌术后肠道粘膜免疫功能紊乱的临床研究进展[J].中国现代医药杂志,10(3):122-124.
[4] Sereda MJ. Purines2010: Adenine Nucleosides and Nucleotides inBiomedicine [J]. IDrugs.2010,13(8):534-8.
[5]周晓东，吕农华.结直肠癌的流行病学研究现状[J].现代消化及介入诊疗,11(3):149-151.
[6]刘启志,傅传刚. Ｋ-ras基因与结直肠癌靶向治疗的研究现状[J].结直肠肛门外科,2012,18(1):63-66.
[7] Cammarota R, Bertolini V, Pennesi G, et al. The tumor microenvironment ofcolorectal cancer: stromal TLR-4expression as a potential prognostic marker[J]. J Transl Med.2010,8(8):112.
[8] Beauchemin N. The colorectal tumor microenvironment: the next decade[J].Cancer Microenviron.2011,4(2):181-5.
[9] Khanna C, Hunter K. Modeling metastasis in vivo [J]. Carcinogenesis.2005,26(3):513-23.
[10] Dong-Mei Li, Jun Zhang, Wen-Mei Li, et al. MAWBP and MAWD inhibitproliferation and invasion in gastric cancer [J]. World J Gastroenterol.2013,19(18):2781–2792.
[11] van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment:molecular insights, antitumor effects, and clinical utility[J]. Oncologist.2006,11(4):397-408.
[12] Katz LH, Li Y, Chen JS, Mu oz NM, et al. Targeting TGF-β signaling incancer [J]. Expert Opin Ther Targets.2013,17(7):743-60.
[13] Hristov AC, Cope L, Di Cello F, et al. HMGA1correlates with advanced tumorgrade and decreased survival in pancreatic ductal adenocarcinoma [J]. ModPathol.2010,23(1):98-104.
[14] Radfar S, Martin H, Tilkin-Mariame AF. Tumor escape mechanism involvingFas and Fas-L molecules in human colorectal tumors [J]. Gastroenterol ClinBiol.2000,24(12):1191-6.
[15] Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumorprogression in colorectal cancer by inhibition of IL-6trans-signaling [J].Immunity.2004,21(4):491-501.
[16] Harpio R, Einarsson R. S100proteins as cancer biomarkers with focus onS100B in malignant melanoma [J]. Clin Biochem.2004,37(7):512-8.
[17] Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer:reassessing the target [J]. Cancer Res.2012,72(8):1909-14.
[18] Bloland P, Simone P, Burkholder B, et al. The role of public health institutionsin global health system strengthening efforts: the US CDC's perspective [J].PLoS Med.2012,9(4): e1001199.
[19] Min Zhao, Jingchun Sun, Zhongming Zhao, et al. TSGene: a web resource fortumor suppressor genes [J]. Nucleic Acids Res.2013,41(D1): D970–D976.
[20] Glinsky GV, Krones-Herzig A, Glinskii AB. Malignancy-associated regions oftranscriptional activation: gene expression profiling identifies commonchromosomal regions of a recurrent transcriptional activation in human prostate,breast, ovarian, and colorectal cancers [J]. Neoplasia.2003,5(3):218-28.
[21] Van de Ven WJ. Genetic basis of uterine leiomyoma: involvement of highmobility group protein genes [J]. Eur J Obstet Gynecol Reprod Biol.1998,81(2):289-93.
[22] Dou Y, Song X, Liu Y, et al. The H1phosphorylation state regulates expressionof CDC2and other genes in response to starvation in Tetrahymena thermophila[J]. Mol Cell Biol.2005,25(10):3914-22.
[23]侯春晖，黄建，张树冰，等. H MG l/Z和H MG14/17与人公珠蛋白基因启动子D N A的相互作用[J].科学通报,2002,47(14):1079-1082.
[24] Ge H, Roeder RG. The high mobility group protein HMG1can reversihlyinhibit classII gene transcription by interaction with the TATA-binding protein[J]. JBC,1994,269(25):17136-17140.
[25]徐佳，刘志锋，姜勇.高迁移率族蛋白与真核基因表达调控[J].生物化学与生物物理进展,2005,32(5):397-402.
[26] Aravind L, Landsman D. AT-hook motifs identified in a wide variety of DNA-binding proteins [J]. Nucleic Acids Res.1998,26(19):4413-21.
[27] Shimahara H, Hirano T, Ohya K, et al. Nucleosome structural changes inducedby binding of non-histone chromosomal proteins HMGN1and HMGN2[J].FEBS Open Bio.2013,28(3):184–191.
[28]李小凤，夏云.高速泳动族蛋白1的致炎症作用机制[J].生命的化学,2012,32(3):236-241.
[29] Lonskaya I, Potaman VN, Shlyakhtenko LS, et al. Regulation of poly(ADP-ribose) polymerase-1by DNA structure-specific binding [J].J Biol Chem2005,280(17):17076-17083.
[30]肖湘文，周建林，周畅.高迁移率族蛋白[J].细胞生物学杂志,2006,28(4):501-506.
[31] Ner SS, Travers AA. HMG-D, the Drosophila melanogaster homologue ofHMG1protein, is associated with early embryonic chromatin in the absence ofhistone H1[J]. EMBO J.1994,13(8):1817-22.
[32] Pallier C, Scaffidi P, Chopineau-Proust S, et al. Association of chromatinproteins high mobility group box (HMGB)1and HMGB2with mitoticchromosomes [J]. Mol Biol Cell.2003,14(8):3414-26.
[33]董小倩，冯云.高迁移率族蛋白N家族抗肿瘤活性的研究进展[J].国际口腔医学杂志,2013,40(3):364-367.
[34] Braet C, Stephan H, Dobbie IM, et al. Mobility and distribution of replicationprotein A in living cells using fluorescence correlation spectroscopy [J]. Exp MolPathol.2007,82(2):156-62.
[35] Kugler JE, Deng T, Bustin M. The HMGN family of chromatin-bindingproteins: dynamic modulators of epigenetic processes [J]. Biochim BiophysActa.2012,1819(7):652-6.
[36] West KL, Castellini MA, Duncan MK, et al. Chromosomal proteins HMGN3aand HMGN3b regulate the expression of glycine transporter1[J].Mol Cell Biol.2004,24(9):3747-56.
[37] Hassa PO, Haenni SS, Elser M, et al. Nuclear ADP-ribosylation reactions inmammalian cells: where are we today and where are we going?[J]. MicrobiolMol Biol Rev.2006,70(3):789-829.
[38] Elenkov I, Pelovsky P, Ugrinova I, et al. The DNA binding and bendingactivities of truncated tail-less HMGB1protein are differentially affected byLys-2and Lys-81residues and their acetylation [J]. Int J Biol Sci.2011,7(6):691-9.
[39] Zhang Q, Wang Y. HMG modifications and nuclear function [J]. BiochimBiophys Acta.2010,1799(1-2):28-36.
[40] Pogna EA, Clayton AL, Mahadevan LC. Signalling to chromatin through post-translational modifications of HMGN [J]. Biochim Biophys Acta.2010,1799(1-2):93-100.
[41] Beitzel B, Bushman F. Construction and analysis of cells lacking the HMGAgene family [J]. Nucleic Acids Res.2003,31(17):5025-32.
[42] Hu X, Jiang H, Bai Q, et al. Increased serum HMGB1is related to the severityof coronary artery stenosis [J]. Clin Chim Acta.2009,406(1-2):139-42.
[43]彭芳，赵力，王国付，等. HMGA1在肺癌中的表达及临床病理学意义[J].健康研究,2013,33(2):97-102.
[44] Esposito F, Tornincasa M, Federico A, et al. High-mobility group A1proteininhibits p53-mediated intrinsic apoptosis by interacting with Bcl-2atmitochondria [J]. Cell Death Dis.2012,30(3): e383.
[45] Biasco L, Baricordi C, Aiuti A. Retroviral integrations in gene therapy trials[J].Mol Ther.2012,20(4):709-16.
[46] Bushman FD. Retroviral integration and human gene therapy [J]. J Clin Invest.2007,117(8):2083-6.
[47] Brown MS, Goldstein JL. Scientific side trips: six excursions from the beatenpath [J]. J Biol Chem.2012,287(27):22418-35.
[48] Preston SL, Alison MR, Forbes SJ, et al. The new stem cell biology: something foreveryone [J]. Mol Pathol.2003,56(2):86-96.
[49]颜丙超，范月超. MicroRNA let-7与HMGA2在垂体腺瘤中的相互关系[J].国际神经病学神经外科学杂志,2012,39(6):576-580.
[50]杨霞，李国华. HMGA1与肿瘤的研究进展[J].江西医药,2009,44(1):79-82.
[51] Dement GA, Maloney SC, Reeves R. Nuclear HMGA1nonhistone chromatinproteins directly influence mitochondrial transcription, maintenance, and function[J]. Exp Cell Res.2007,313(1):77-87.
[52] Donald LJ, Hosfield DJ, Cuvelier SL, et al. Mass spectrometric study of theEscherichia coli repressor proteins, Ic1R and Gc1R, and their complexes withDNA [J]. Protein Sci.2001,10(7):1370-80.
[53] Tugarinov V, Hwang PM, Kay LE. Nuclear magnetic resonance spectroscopyof high-molecular-weight proteins [J]. Annu Rev Biochem.2004,73:107-46.
[54] Zhang Q, Wang Y. HMG Modifications and Nuclear Function [J]. BiochimBiophys Acta.2010,1799(1-2):28-36.
[55] Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of thehuman genome [J]. Nature.2001,409(6822):860-921.
[56] Popescu NC, King CR, Kraus MH. Localization of the human erbB-2gene onnormal and rearranged chromosomes17to bands q12-21.32[J]. Genomics.1989,4(3):362-6.
[57] Gurova K. New hopes from old drugs: revisiting DNA-binding small moleculesas anticancer agents [J]. Future Oncol.2009,5(10):1685-704.
[58] Fan H, Guo H, Zhang IY, et al. The different HMGA1expression of totalpopulation of glioblastoma cell line U251and glioma stem cells isolated fromU251[J]. Brain Res.2011,1384:9-14.
[59] Vervoort SJ, van Boxtel R, Coffer PJ. The role of SRY-related HMG boxtranscription factor4(SOX4) in tumorigenesis and metastasis: friend or foe?[J].Oncogene.2013,32(29):3397-409.
[60] Coppotelli G, Mughal N, Callegari S, et al. The Epstein-Barr virus nuclear antigen-1reprograms transcription by mimicry of high mobility group A proteins [J]. NucleicAcids Res.2013,41(5):2950-62.
[61] Goldfine ID. The insulin receptor: molecular biology and transmembranesignaling [J]. Endocr Rev.1987,8(3):235-55.
[62] Vogel B, L schberger A, Sauer M, et al. Cross-linking of DNA throughHMGA1suggests a DNA scaffold [J]. Nucleic Acids Res.2011,39(16):7124-33.
[63] Edberg DD, Adkins JN, Springer DL, et al. Dynamic and differential in vivomodifications of the isoform HMGA1a and HMGA1b chromatin proteins [J]. J BiolChem.2005,280(10):8961-73.
[64] Crevel G, Huikeshoven H, Cotterill S. Df31is a novel nuclear protein involvedin chromatin structure in Drosophila melanogaster [J]. J Cell Sci.2001,114(Pt1):37-47.
[65] Smith EM, Proud CG. cdc2-cyclin B regulates eEF2kinase activity in a cellcycle-and amino acid-dependent manner [J]. EMBO J.2008,27(7):1005-16.
[66] Palmieri D, D'Angelo D, Valentino T, et al. Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis [J].Oncogene.2012,31(34):3857-65.
[67] Lemke I, Rogalla P, Bullerdiek J. A novel LPP fusion gene indicates the crucialrole of truncated LPP proteins in lipomas and pulmonary chondroidhamartomas [J]. Cytogenet Cell Genet.2001,95(3-4):153-6.
[68]张小茜,全先庆,单雷,等.高迁移率族蛋白A的特征及其在转录中的调控[J].生命的化学,2006,26(5):414-417.
[69] Sgarra R, Lee J, Tessari MA, et al. The AT-hook of the chromatin architecturaltranscription factor high mobility group A1a is arginine-methylated by proteinarginine methyltransferase6[J]. J Biol Chem.2006,281(7):3764-72.
[70] Sgarra R, Maurizio E, Zammitti S, et al. Macroscopic differences in HMGAoncoproteins post-translational modifications: C-terminal phosphorylation ofHMGA2affects its DNA binding properties [J]. J Proteome Res.2009,8(6):2978-89.
[71] García-Heras F, Abellón-Ruiz J, Murillo FJ, et al. High-mobility-group a-likeCarD binds to a DNA site optimized for affinity and position and to RNApolymerase to regulate a light-inducible promoter in Myxococcus xanthus[J]. JBacteriol.2013,195(2):378-88.
[72] Panne D, Maniatis T, Harrison SC. An atomic model of the interferon-betaenhanceosome [J]. Cell.2007,129(6):1111-23.
[73] Reményi A, Lins K, Nissen LJ, et al. Crystal structure of a POU/HMG/DNAternary complex suggests differential assembly of Oct4and Sox2on twoenhancers [J]. Genes Dev.2003,17(16):2048-59.
[74] Mao L, Wertzler KJ, Maloney SC, et al. HMGA1levels influencemitochondrial function and mitochondrial DNA repair efficiency [J]. Mol CellBiol.2009,9(20):5426-40.
[75] Jayaraman L, Moorthy NC, Murthy KG, et al. High mobility group protein-1(HMG-1) is a unique activator of p53[J]. Genes Dev.1998,12(4):462-72.
[76] Singh BN, Zhang G, Hwa YL, et al. Nonhistone protein acetylation as cancertherapy targets[J]. Expert Rev Anticancer Ther.2010,10(6):935-54.
[77] Mukherjee A, Melnattur KV, Zhang M, et al. Maternal expression and functionof the Drosophila sox gene Dichaete during oogenesis [J]. Dev Dyn.2006,235(10):2828-35.
[78] Baron RM, Lopez-Guzman S, Riascos DF, et al. Distamycin A inhibitsHMGA1-binding to the P-selectin promoter and attenuates lung and liverinflammation during murine endotoxemia [J]. PLoS One.2010,5(5): e10656.
[79] Dekker J, Marti-Renom MA, Mirny LA. Exploring the three-dimensionalorganization of genomes: interpreting chromatin interaction data [J]. Nat RevGenet.2013,14(6):390-403.
[80] Baltz JL, Filman DJ, Ciustea M, et al. The crystal structure of PF-8, the DNApolymerase accessory subunit from Kaposi's sarcoma-associated herpesvirus [J].J Virol.2009,83(23):12215-28.
[81] Bustin M. Regulation of DNA-dependent activities by the functional motifs ofthe high-mobility-group chromosomal proteins [J]. Mol Cell Biol.1999,19(8):5237-46.
[82] Dement GA, Treff NR, Magnuson NS, et al. Dynamic mitochondriallocalization of nuclear transcription factor HMGA1[J]. Exp Cell Res.2005,307(2):388-401.
[83] Di Cello F, Shin J, Harbom K, et al. Knockdown of HMGA1inhibits humanbreast cancer cell growth and metastasis in immunodeficient mice [J]. BiochemBiophys Res Commun.2013,434(1):70-4.
[84] Miranda TB, Webb KJ, Edberg DD, et al. Protein arginine methyltransferase6specifically methylates the nonhistone chromatin protein HMGA1a [J].Biochem Biophys Res Commun.2005,336(3):831-5.
[85] Falvo JV, Lin CH, Tsytsykova AV, et al. A dimer-specific function of thetranscription factor NFATp [J]. Proc Natl Acad Sci U S A.2008,105(50):19637-42.
[86] Nezhad MH, Drieschner N, Helms S, et al.6p21rearrangements in uterineleiomyomas targeting HMGA1[J]. Cancer Genet Cytogenet.2010,203(2):247-52.
[87] Chiefari E1, Arcidiacono B1, Possidente K1, et al. Transcriptional Regulationof the HMGA1Gene by Octamer-Binding Proteins Oct-1and Oct-2[J]. PLoSOne.2013,8(12):e83969.
[88] Chiappetta G, Avantaggiato V, Visconti R, et al. High level expression of theHMGI (Y) gene during embryonic development [J]. Oncogene.1996,13(11):2439-46.
[89] Catez F, Yang H, Tracey KJ, et al. Network of dynamic interactions betweenhistone H1and high-mobility-group proteins in chromatin [J]. Mol Cell Biol.2004,24(10):4321-8.
[90] Akaboshi S, Watanabe S, Hino Y, et al. HMGA1is induced by Wnt/beta-catenin pathway and maintains cell proliferation in gastric cancer [J]. Am JPathol.2009,175(4):1675-85.
[91] Yoshida Y, Shibata T, Kokubu A, et al. Mutations of the epidermal growthfactor receptor gene in atypical adenomatous hyperplasia andbronchioloalveolar carcinoma of the lung [J]. Lung Cancer.2005,50(1):1-8.
[92]许永华，李长贤，陈杰，等.高迁移率族蛋白A1（HMGA1）在肝细胞癌中的表达及临床意义[J].南京医科大学学报(自然科学版),2010,30(3):304-308.
[93] Mansueto G, Forzati F, Ferraro A, et al. Identification of a New Pathway forTumor Progression: MicroRNA-181b Up-Regulation and CBX7Down-Regulation by HMGA1Protein [J]. Genes Cancer.2010,1(3):210-24.
[94] Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer:new insights into mechanisms, progression, and target identification [J]. J ClinOncol.2006,24(35):5552-64.
[95] Takeuchi I, Takaha N, Nakamura T, et al. High mobility group protein AT-hook1(HMGA1) is associated with the development of androgenindependence in prostate cancer cells [J]. Prostate.2012,72(10):1124-32.
[96] Angeloni C, Pirola L, Vauzour D, et al. Dietary polyphenols and their effects oncell biochemistry and pathophysiology [J]. Oxid Med Cell Longev.2012,2012:583901
[97] Mao L, Wertzler KJ, Maloney SC, et al. HMGA1levels influencemitochondrial function and mitochondrial DNA repair efficiency [J]. Mol CellBiol.2009,29(20):5426-40.
[98] Hillion J, Smail SS, Di Cello F, et al. The HMGA1-COX-2axis: a keymolecular pathway and potential target in pancreatic adenocarcinoma[J].Pancreatology.2012,12(4):372-9.
[99] Leroux-Roels I, Leroux-Roels G, Ofori-Anyinam O, et al. Evaluation of thesafety and immunogenicity of two antigen concentrations of theMtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults [J]. Clin Vaccine Immunol.2010,17(11):1763-71.
[100]Venkatesan N, Krishnakumar S, Deepa PR, et al. Molecular deregulationinduced by silencing of the high mobility group protein A2gene inretinoblastoma cells [J]. Mol Vis.2012,18:2420-37.
[101]Shah SN, Cope L, Poh W, et al. HMGA1: a master regulator of tumorprogression in triple-negative breast cancer cells [J]. PLoS One.2013,8(5):e63419.
[102]Kang MI, Baker AR, Dextras CR, et al. Targeting of Noncanonical Wnt5aSignaling by AP-1Blocker Dominant-Negative Jun When It Inhibits SkinCarcinogenesis [J]. Genes Cancer.2012,3(1):37-50.
[103]Wang C, Chen T, Zhang J, et al. The E3ubiquitin ligase Nrdp1'preferentially'promotes TLR-mediated production of type I interferon [J]. Nat Immunol.2009,10(7):744-52.
[104]Burrows AC, Prokop J, Summers MK. Skp1-Cul1-F-box ubiquitin ligase(SCF(βTrCP))-mediated destruction of the ubiquitin-specific protease USP37during G2-phase promotes mitotic entry [J]. J Biol Chem.2012,287(46):39021-9.
[105]Dhar A, Hu J, Reeves R, Resar LM, et al. Dominant-negative c-Jun (TAM67)target genes: HMGA1is required for tumor promoter-induced transformation[J]. Oncogene.2004,23(25):4466-76.
[106]Erkan M, Reiser-Erkan C, Michalski CW, et al. Tumor microenvironment andprogression of pancreatic cancer [J]. Exp Oncol.2010,32(3):128-31.
[107]Reuter S, Gupta SC, Chaturvedi MM, et al. Oxidative stress, inflammation, andcancer: how are they linked?[J]. Free Radic Biol Med.2010,49(11):1603-16.
[108]Lonkar P, Dedon PC. Reactive species and DNA damage in chronicinflammation: reconciling chemical mechanisms and biological fates [J]. Int JCancer.2011,128(9):1999-2009.
[109]Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervicalcancer [J]. Lancet.2007,370(9590):890-907.
[110]Zhu S, Wu H, Wu F, et al. MicroRNA-21targets tumor suppressor genes ininvasion and metastasis [J]. Cell Res.2008,18(3):350-9.
[111]Ryu CH, Park KY, Hou Y, et al. Gene therapy of multiple sclerosis usinginterferon β-secreting human bone marrow mesenchymal stem cells [J].Biomed Res Int.2013,2013:696738.
[112]Baldassarre G, Battista S, Belletti B, et al. Negative regulation of BRCA1geneexpression by HMGA1proteins accounts for the reduced BRCA1proteinlevels in sporadic breast carcinoma [J]. Mol Cell Biol.2003,23(7):2225-38.
[113]Wu J, Liu Z, Shao C, et al. HMGA2overexpression-induced ovarian surfaceepithelial transformation is mediated through regulation of EMT genes [J].Cancer Res.2011,71(2):349-59.
[114]Wang EL, Qian ZR, Rahman MM, et al. Increased expression of HMGA1correlates with tumour invasiveness and proliferation in human pituitaryadenomas [J]. Histopathology.2010,56(4):501-9.
[115]Scala S, P.G., Fedele M, Chiappetta G, et al.Adenovirus-mediated suppressionof HMGI(Y) protein synthesis as potential therapy of human malignantneoplasias [J]. Proc Natl Acad Sci USA,2000,97(8): p.4256-4261
[116]Trapasso F, S.M., Cesari R, Yendamuri S, et al. Therapy of human pancreaticcarcinoma based on suppression of HMGA1protein synthesis in preclinicalmodels [J]. Cancer Gene Ther,2004.11(9): p.633-641.
[117]Liau SS, Jazag A, Ito K, et al. Overexpression of HMGA1promotes anoikisresistance and constitutive Akt activation in pancreatic adenocarcinoma cells[J]. Br J Cancer.2007,96(6):993-1000.
[118]Reeves R, E.D., Li Y.Architectural transcription factor HMG1(Y) promotestumour progression and mesenchymal transition of human epithelial cells [J].Mol Cell Biol,2001.21: p.575-584.
[119]Wieghaus KA, Gianchandani EP, Neal RA, et al. Phthalimide neovascularfactor1(PNF1) modulates MT1-MMP activity in human microvascularendothelial cells [J]. Biotechnol Bioeng.2009,103(4):796-807.
[120]J rvel inen H, Sainio A, Koulu M, et al. Extracellular matrix molecules:potential targets in pharmacotherapy [J]. Pharmacol Rev.2009,61(2):198-223.
[121]E, G.F.a.R. Integrin signaling. Science,1999.285: p.1028-1032.
[122]Salmans ML, Zhao F, Andersen B. The estrogen-regulated anterior gradient2(AGR2) protein in breast cancer: a potential drug target and biomarker [J].Breast Cancer Res.2013,24;15(2):204.
[123]Serini G, Bochaton-Piallat ML, Ropraz P, et al. Tumor growth modeling fromthe perspective of multiphase porous media mechanics [J]. Mol Cell Biomech.2012,9(3):193-212.
[124]Hunter SE, Jung D, Di Giulio RT, et al. The QPCR assay for analysis ofmitochondrial DNA damage, repair, and relative copy number [J]. Methods.2010,51(4):444-51.
[125]Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview ofresistance to systemic therapy in patients with breast cancer [J]. Adv Exp MedBiol.2007,608:1-22.
[126]Geng M, Wang L, Li P. Correlation between chemosensitivity to anticancerdrugs and Bcl-2expression in gastric cancer [J]. Int J Clin Exp Pathol.2013,6(11):2554-9.
[127]Gustafson DH, Shaw BR, Isham A, et al. Explicating an evidence-based,theoretically informed, mobile technology-based system to improve outcomesfor people in recovery for alcohol dependence [J]. Subst Use Misuse.2011,46(1):96-111.
[128]Fernandez Tde S, de Souza Fernandez C, Mencalha AL. Human inducedpluripotent stem cells from basic research to potential clinical applications incancer [J]. Biomed Res Int.2013;2013:430290.
[129]Chen CZ, Schaffert S, Fragoso R, et al. Regulation of immune responses andtolerance: the microRNA perspective [J]. Immunol Rev.2013,253(1):112-28.
[130]Que JU, Casey SW, Hentges DJ. Factors responsible for increasedsusceptibility of mice to intestinal colonization after treatment withstreptomycin [J]. Infect Immun.1986,53(1):116-23.
[131]Jeong SH, Kang D, Lim MW, et al. Risk assessment of growth hormones andantimicrobial residues in meat [J]. Toxicol Res.2010,26(4):301-13.
[132]Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancerprogression: biology and implications for treatment [J]. Breast Cancer Res.2011,13(6):227.
[133]Liau SS, A.S.a.W.E.Lentivirus-mediated RNA interference of HMGA1promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma [J]. JGastrointest Surg,2006.10(9): p.1254-1262.
[134]Liau SS, Ashley SW, Whang EE. Lentivirus-mediated RNA interference ofHMGA1promotes chemosensitivity to gemcitabine in pancreaticadenocarcinoma [J]. J Gastrointest Surg.2006,10(9):1254-62.
[135]Xu M, Sharma P, Pan S, et al. Core promoter-selective function of HMGA1and Mediator in Initiator-dependent transcription [J]. Genes Dev.2011,25(23):2513-24.
[136]Zhang Q, Wang Y. HMG modifications and nuclear function [J]. BiochimBiophys Acta.2010,1799(1-2):28-36.
[137]L, R.R.a.B. HMGI/Y proteins: flexible regulators of transcription andchromatin structure [J]. Biochim Biophys Acta,2001,1519(1-2): p.13-29.
[138]Pierantoni GM, Rinaldo C, Esposito F, et al. Retraction: High Mobility GroupA1(HMGA1) proteins interact with p53and inhibit its apoptotic activity [J].Cell Death Differ.2014,21(3):503.
[139]Pierantoni GM, Rinaldo C, Mottolese M, et al. High-mobility group A1inhibitsp53by cytoplasmic relocalization of its proapoptotic activator HIPK2[J]. JClin Invest.2007,117(3):693-702.
[140]Wajed SA, Laird PW, DeMeester TR. DNA methylation: an alternativepathway to cancer [J]. Ann Surg.2001,234(1):10-20.
[141]Veschi V, Petroni M, Cardinali B, et al. Galectin-3impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3inneuroblastoma cells [J]. PLoS One.2012,7(11): e49139.
[142]Adair JE, K.Y., Dement GA, Smerdon MJ, et al. Inhibition of nucleotideexcision repair by high mobility group protein HMGA1[J]. J Biol Chem,2005.280(37): p.32184-32192.
[143]Dement GA, T.N., Magnuson NS, Franceschi V, et al. Dynamic mitochondriallocalization of nuclear transcription factor HMGA1[J]. Exp Cell Res.,2005,307(2): p.388-401.
[144]1443. Dement GA, M.S., Reeves R. Nuclear HMGA1nonhistone chromatinproteins directly influence mitochondrial transcription, maitenance, andfunction [J]. Exp Cell Res.,2007,313(1): p.77-87.
[145]Treff NR, D.G., Adair JE, Britt RL, et al. Human KIT ligand promoter ispositively regulated by HMGA1in breast and ovarian cancer cells [J].Oncogene,2004,23(52): p.8557-8562.
[146]Lenard NR, Berthoud HR. Central and peripheral regulation of food intake andphysical activity: pathways and genes [J]. Obesity (Silver Spring).2008,16Suppl3: S11-22.
[147]Hock R, Furusawa T, Ueda T, et al. HMG chromosomal proteins indevelopment and disease [J]. Trends Cell Biol.2007,17(2):72-9.
[148]Moskwa P, Buffa FM, Pan Y, et al. miR-182-mediated downregulation ofBRCA1impacts DNA repair and sensitivity to PARP inhibitors [J]. Mol Cell.2011,41(2):210-20.
[149]Panda AC, Grammatikakis I, Yoon JH, et al. Posttranscriptional regulation ofinsulin family ligands and receptors [J]. Int J Mol Sci.2013,14(9):19202-29.
[150]Diana F, S.R., Manfioletti G, Rustighi A, et al. A link between apoptosis anddegree of phosphorylation of high mobility group A1a protein in leukemic cells.J Biol Chem.,2001,276(14): p.11354-11361.
[151]Kleindienst A, Harvey HB, Rice AC, et al. Intraventricular infusion of theneurotrophic protein S100B improves cognitive recovery after fluid percussioninjury in the rat[J]. J Neurotrauma.2004,21(5):541-7.
[152]Yanyi C, Shenghui X, Yubin Z, et al. Calciomics: prediction and analysis ofEF-hand calcium binding proteins by protein engineering [J]. Sci China Chem.2010,53(1):52-60.
[153]Keijser S, Missotten GS, Bonfrer JM, et al. Immunophenotypic markers todifferentiate between benign and malignant melanocytic lesions [J]. Br JOphthalmol.2006,90(2):213-7.
[154]Moroz OV, Burkitt W, Wittkowski H, et al. Both Ca2+and Zn2+are essentialfor S100A12protein oligomerization and function [J]. BMC Biochem.2009,3.10:11.
[155]Takizawa T, Takizawa T, Arai S, et al. Ultrastructural localization of S100A3,a cysteine-rich, calcium binding protein, in human scalp hair shafts revealed byrapid-freezing immunocytochemistry [J]. J Histochem Cytochem.1999,47(4):525-32.
[156]Ilg EC, Sch fer BW, Heizmann CW. Expression pattern of S100calcium-binding proteins in human tumors [J]. Int J Cancer.1996,68(3):325-32.
[157]Webb M, Emberley ED, Lizardo M, et al. Expression analysis of the mouseS100A7/psoriasin gene in skin inflammation and mammary tumorigenesis [J].BMC Cancer.2005,17，5:17.
[158]Goldstone R, Itzkowitz S, Harpaz N, et al. Dysplasia is more common in thedistal than proximal colon in ulcerative colitis surveillance [J]. Inflamm BowelDis.2012,18(5):832-7.
[159]Ia tski NA, Gelazoniia RV, Khatelishvili VM. Surgical treatment of cancer ofthe colon involving adjacent organs and tissue [J]. Vestn Khir Im I I Grek.1988,140(1):58-60.
[160]Aparo S, Goel S. Evolvement of the treatment paradigm for metastatic coloncancer. From chemotherapy to targeted therapy [J]. Crit Rev Oncol Hematol.2012,83(1):47-58.
[161]Blagosklonny MV. Common drugs and treatments for cancer and age-relateddiseases: revitalizing answers to NCI's provocative questions [J]. Oncotarget.2012,3(12):1711-24.
[162]Daniels AL, Van Slambrouck S, Lee RK, et al. Effects of extracts from twoNative American plants on proliferation of human breast and colon cancer celllines in vitro [J]. Oncol Rep.2006,15(5):1327-31.
[163]曾芳,李媛.大黄有效化学成分及其药理作用[J].当代医学,2013,19(12):149.
[164]姜晓峰,甄永苏.大黄素逆转肿瘤细胞多药抗药性的作用[J].药学学报,1999,34(3)∶164-167.
[165]Chun-Guang W, Jun-Qing Y, Bei-Zhong L, et al. Anti-tumor activity ofemodin against human chronic myelocytic leukemia K562cell lines in vitroand in vivo [J]. Eur J Pharmacol.2010,627(1-3):33-41.
[166]吕盈盈,钱家鸣,邱辉忠.大黄素对结直肠癌血管内皮生长因子受体的影响及对结直肠癌抑制作用的研究[J].中国中西医结合消化杂志,2005,13(5):310-313.
[167]李进，冯成强，张文生.冬虫夏草研究回顾与展望[J].农业资源与环境科学，2008，24(2):382–384.
[168]雷万生,谢联斌,陈和平.冬虫夏草的研究概况[J].海军医学杂志,2006,27(3):262-269.
[169]黄浩,王航,罗荣城.冬虫夏草提取液抑制结直肠癌细胞增殖的研究[J].中药材,2007,30(3):310-313.
[170]Huang H, Wang H, Luo RC. Inhibitory effects of cordyceps extract on growthof colon cancer cells [J]. Zhong Yao Cai.2007,30(3):310-3.
[171]黄赞松，周喜汉.苦参素药理和抗肿瘤作用研究[J].医学综述，2005，15(11):1701-1703.
[172]Lu LG, Zeng MD, Mao YM, et al. Oxymatrine therapy for chronic hepatitis B:a randomized double-blind and placebo-controlled multi-center trial [J]. WorldJ Gastroenterol.2003,9(11):2480-3.
[173]Olaku O, White JD. Herbal therapy use by cancer patients: a literature reviewon case reports [J]. Eur J Cancer.2011,47(4):508-14.
[174]阳巍，廖端芳，庹勤慧.姜黄素抗动脉粥样硬化研究进展[J].国际病理科学与临床杂志,2012,32(1):55-58.
[175]郑玉强，邓立普.姜黄素药理作用研究进展[J].辽宁中医药大学学报,2012,11(2):212-214.
[176]余美荣，蒋福升，丁志山.姜黄素的研究进展[J].中草药，2009，40(5)：828-831.
[177]任贻军，高逢喜.黄连素的研究进展[J].辽宁中医药大学学报,2009,11(1):50-51.
[178]李晓苗，王海军，李源，等.黄连素降糖作用机制研究进展[J].陕西医学杂志,2012,41(11):1547-1549.
[179]郭学敏,洪永福,周桌轮.毛蓖属植物化学成分研究概况[J].中草药,1995,26(10):550-551.
[180]王海燕,赵雪花,何丽娅.黄连素抗癌作用的分子机制[J].中国药房,2007,18(3):221-223.
[181]陆宁,王邦茂,黄迺侠,等.黄连素对脱氧胆酸诱导的人结直肠癌细胞株增殖抑制作用及机制[J].中华消化医学,2006,26(9):632-633.
[182]乐崇熙，楼之岑.中药天花粉及其类似品德鉴别研究[J].药学学报，1979,14(11):641-651.
[183]王海英，刘旭.东天花粉抗肿瘤研究进展[J].国医论坛,2005,20(1):54–55.
[184]林国庆,邵靖宇.天花粉蛋白研究新进展[J].科技通报,1996,12(2):122-125.
[185]王英俊,付莉,华海婴.黄芩苷诱导结直肠癌细胞株SW21116凋亡的研究[J].中医研究,2007,20(6):22-23.
[186]李森林,肖文海,黄岩.斑蝥的现代药理研究和临床应用[J].中国社区医师(综合版).2007,169(9):16.
[187]李森朋，谭学杰，赵云雪，等.脱氢脱甲基斑蝥酸银配聚物体内外抗肿瘤活性研究[J].中国药理学通报.2013，(12):1774-1775.
[188]姚燕丹，林少芒.去甲斑蝥素的研究进展及其与乳腺癌的关系[J].中国医药导刊,2005,7(1):58.
[189]江励华，王明艳.斑蝥的研究[J].医药导报,2004,23(6):385.
[190]安中原,王正,赵越.斑蝥素及其衍生物的抗肿瘤研究进展[J].亚太传统医药,2009,5(1):128-130.
[191]191.尹璇,陈志伟.斑蝥素及其药理作用研究进展[J].生命科学仪器,2009,7(3):3-6.
[192]Barrett TW, Peticolas WL, Robson RM. Laser Raman light-scatteringobservations of conformational changes in myosin induced by inorganic salts[J]. Biophys J.1978,23(3):349-58.
[193]龚,卢永凯,林素君,等.拉曼光谱技术在色谱分析检测中的应用[J].化学通报,2010,8:689-692.
[194]胡晓红,周金池.拉曼光谱的应用及其进展[J].分析仪器,2011,6:1-4.
[195]刘玲.激光拉曼光谱及其应用进展[J].山西大学学报(自然科学版),2001,24(3):279-282.
[196]王敏,俞帆,隆泉.激光拉曼光谱在蛋白质构象研究中的应用和进展[J].激光生物学报,2006,16(4):516-520.
[197]陆天虹.表面增强拉曼光谱及其在化学中的应用[J].腐蚀科学与防护技术,1995,7(2):102-107.
[198]Cardoso MM, Pe a IN, Roque AC. Antibody-conjugated nanoparticles fortherapeutic applications [J]. Curr Med Chem.2012,19(19):3103-27.
[199]Arias JL, López-Viota M, Ruiz MA, et al. Development of carbonyliron/ethylcellulose core/shell nanoparticles for biomedical applications [J]. Int JPharm.2007,339(1-2):237-45.
[200]Ong YH, Lim M, Liu Q. Comparison of principal component analysis andbiochemical component analysis in Raman spectroscopy for the discriminationof apoptosis and necrosis in K562leukemia cells [J]. Opt Express.2012,20(20):22158-71.
[201]Pharoah PD, Guilford P, Caldas C, et al. Incidence of gastric cancer and breastcancer in CDH1(E-cadherin) mutation carriers from hereditary diffuse gastriccancer families [J]. Gastroenterology.2001,12(6):1348-53.
[202]de la Torre NG, Buley I, Wass JA, et al. Angiogenesis and lymphangiogenesis inthyroid proliferative lesions: relationship to type and tumour behavior [J].Endocr Relat Cancer.2006,13(3):931-44.
[203]Huang Z, McWilliams A, Lui H, et al. Near-infrared Raman spectroscopy foroptical diagnosis of lung cancer [J]. Int J Cancer.2003,107(6):1047-52.
[204] Panikkanvalappil SR, Mackey MA, El-Sayed MA. Probing the uniquedehydration-induced structural modifications in cancer cell DNA using surfaceenhanced Raman spectroscopy [J]. J Am Chem Soc.2013,135(12):4815-21.
[205] Kendall C, Stone N, Shepherd N, et al. Raman spectroscopy, a potential tool forthe objective identification and classification of neoplasia in Barrett'soesophagus [J]. J Pathol.2003,200(5):602-9.
[206]Amersi F, Agustin M, Ko CY. Colorectal cancer: epidemiology, risk factors,and health services [J]. Clin Colorectal Rectal Surg.2005,18(3):133-40.
[207]Kovoor PA, Hwang J. Treatment of resectable gastric cancer: current standardsof care [J]. Expert Rev Anticancer Ther.2009,9(1):135-42.
[208]Ioka T, Ishikawa H, Akedo I, et al. Study of Prevention of Colorectal Cancerthrough Lifestyle Modification: an Introduction to the Protocol [J]. Asian Pac JCancer Prev.2001,2(3):233-236.
[209]Choong MK, Tsafnat G. Genetic and epigenetic biomarkers of colorectalcancer [J]. Clin Gastroenterol Hepatol.2012,10(1):9-15.
[210]Yao R, Lopez-Beltran A, Maclennan GT, et al. Expression of S100proteinfamily members in the pathogenesis of bladder tumors [J]. Anticancer Res.2007,27(5A):3051-8.
[211]Wei JJ, Wu X, Peng Y, et al. Regulation of HMGA1expression by microRNA-296affects prostate cancer growth and invasion [J]. Clin Cancer Res.2011,17(6):1297-305.
[212] Manuell AL, Beligni MV, Elder JH, et al. Robust expression of a bioactivemammalian protein in Chlamydomonas chloroplast [J]. Plant Biotechnol J.2007,5(3):402-12.
[213]Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality,survival, and risk factors [J]. Clin Colorectal Rectal Surg.2009,22(4):191-7.
[214]Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous systeminduces a metastatic switch in primary breast cancer [J]. Cancer Res.2010,70(18):7042-52.
[215]Lloyd BH, Ruddell C, Rudland PS, et al. S100A3mRNA expression displaysan inverse correlation to breast cancer progression. Biochem Soc Trans1996,24(3):340.
[216]Koontongkaew S. The tumor microenvironment contribution to development,growth, invasion and metastasis of head and neck squamous cell carcinomas [J].J Cancer.2013,4(1):66-83.
[217]Camby I, Lefranc F, Titeca G, et al. Differential expression of S100calcium-binding proteins characterizes distinct clinical entities in both WHO grade IIand III astrocytic tumours [J]. Neuropathol Appl Neurobiol.2000,26(1):76-90.
[218]Ilg EC, Sch fer BW, Heizmann CW. Expression pattern of S100calcium-binding proteins in human tumors [J]. Int J Cancer.1996,68(3):325-32.
[219]Cao Z, Tanguay RL, McKenzie D, et al. Identification of a putative calcium-binding protein as a dioxin-responsive gene in zebrafish and rainbow trout[J].Aquat Toxicol.2003,63(3):271-82.
[220]Liotta L, Petricoin E. Molecular profiling of human cancer [J]. Nat Rev Genet.2000,1(1):48-56.
[221]Wang Z, Feng X, Liu X, et al. Involvement of potential pathways in malignanttransformation from oral leukoplakia to oral squamous cell carcinoma revealedby proteomic analysis [J]. BMC Genomics.2009,10:383.
[222] Morrison RD, Blobaum AL, Byers FW, et al. The role of aldehyde oxidaseand xanthine oxidase in the biotransformation of a novel negative allostericmodulator of metabotropic glutamate receptor subtype5[J]. Drug MetabDispos.2012,40(9):1834-45.
[223]Sarhadi VK, Wikman H, Salmenkivi K, et al. Increased expression of highmobility group A proteins in lung cancer [J]. J Pathol.2006,209(2):206-12.
[224]Dolde CE, Mukherjee M, Cho C, et al. HMG-I/Y in human breast cancer celllines [J]. Breast Cancer Res Treat.2002,71(3):181-91.
[225] Fedele M, Fidanza V, Battista S, et al. Haploinsufficiency of the Hmga1genecauses cardiac hypertrophy and myelo-lymphoproliferative disorders in mice[J]. Cancer Res.2006,66(5):2536-43.
[226].Pierantoni GM, Battista S, Pentimalli F, et al. A truncated HMGA1geneinduces proliferation of the3T3-L1pre-adipocytic cells: a model of humanlipomas [J]. Carcinogenesis.2003,24(12):1861-9.
[227]Groves P, Palczewska M.Cation binding properties of calretinin, an EF-handcalcium-binding protein [J]. Acta Biochim Pol.2001,48(1):113-9.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |